Interim analysis (IA) results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA 4518)Clinical Science Symposium: New Paradigms for Hormone Therapy in Prostate Cancer, Saturday, June 2, 8:00 - 8:15 a.m., E. Arie Crown TheaterLead Author:

RARITAN, N.J., March 8, 2012 /PRNewswire/ -- Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA® (abiraterone acetate) plus prednisone

RARITAN, N.J., Nov. 4, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S.

SOMERSET, N.J., Oct.

SOMERSET, N.J., Sept.